miR-125b-5p delivered by adipose-derived stem cell exosomes alleviates hypertrophic scarring by suppressing Smad2

Abstract

Background: Hypertrophic scarring is the most serious and unmet challenge following burn and trauma injury and often leads to pain, itching and even loss of function. However, the demand for ideal scar prevention and treatment is difficult to satisfy. We aimed to discover the effects and mechanisms of adipose-derived stem cell (ADSC) exosomes in hypertrophic scarring. Methods: ADSC exosomes were isolated from the culture supernatant of ADSCs and identified by nanoparticle tracking analysis, transmission electron microscopy and western blotting. The effect of ADSC exosomes on wound healing and scar formation was detected by the wound model of BALB/c mice. We isolated myofibroblasts from hypertrophic scar tissue and detected the cell viability, proliferation and migration of myofibroblasts. In addition, collagen formation and fibrosis-related molecules were also detected. To further disclose the mechanism of ADSC exosomes on fibrosis in myofibroblasts, we detected the expression of Smad2 in hypertrophic scar tissue and normal skin and the regulatory mechanism of ADSC exosomes on Smad2. Injection of bleomycin was performed in male BALB/c mice to establish an in vivo fibrosis model while ADSC exosomes were administered to observe their protective effect. The tissue injury of mice was observed via hematoxylin and eosin and Masson staining and related testing. Results: In this study, we found that ADSC exosomes could not only speed up wound healing and improve healing quality but also prevent scar formation. ADSC exosomes inhibited expression of fibrosis-related molecules such as α-smooth muscle actin, collagen I (COL1) and COL3 and inhibited the transdifferentiation of myofibroblasts. In addition, we verified that Smad2 is highly expressed in both hypertrophic scar tissue and hypertrophic fibroblasts, while ADSC exosomes downregulated the expression of Smad2 in hypertrophic fibroblasts. Further regulatory mechanism analysis revealed that microRNA-125b-5p (miR-125b-5p) is highly expressed in ADSC exosomes and binds to the 3′ untranslated region of Smad2, thus inhibiting its expression. In vivo experiments also revealed that ADSC exosomes could alleviate bleomycin-induced skin fibrosis and downregulate the expression of Smad2. Conclusions: We found that ADSC exosomes could alleviate hypertrophic scars via the suppression of Smad2 by the specific delivery of miR-125b-5p.

Keywords

Adipose-derived stem cell / Exosomes / Hypertrophic scar / miR-125b-5p / Smad2 / MicroRNA / Skin / Fibrosis

References

[1] Ung CY, Warwick A, Onoufriadis A, Barker JN, Parsons M, McGrath JA, et al. Comorbidities of keloid and hypertrophic scars among participants in UK biobank. JAMA Dermatol. 2023; 159: 172-81.

[2] Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet (London, England). 2016; 388: 1427-36.

[3] Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018; 19: 711. https://doi.org/10.3390/ijms19030711.

[4] Ogawa R.The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg. 2022; 149: 79e-4.

[5] Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017; 18: 606. https://doi.org/10.3390/ijms18030606.

[6] Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017; 43: S3-s18.

[7] Yin J, Zhang S, Yang C, Wang Y, Shi B, Zheng Q, et al. Mechanotransduction in skin wound healing and scar formation: potential therapeutic targets for controlling hypertrophic scarring. Front Immunol. 2022; 13: 1028410.

[8] Shpichka A, Butnaru D, Bezrukov EA, Sukhanov RB, Atala A, Burdukovskii V, et al. Skin tissue regeneration for burn injury. Stem Cell Res Ther. 2019; 10: 94.

[9] Zhang T, Wang XF, Wang ZC, Lou D, Fang QQ, Hu YY, et al. Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed Pharmacother. 2020; 129: 110287.

[10] Wang J, Zhao M, Zhang H, Yang F, Luo L, Shen K, et al. KLF4 alleviates hypertrophic scar fibrosis by directly activating BMP4 transcription. Int J Biol Sci. 2022; 18: 3324-36.

[11] Zhang J, Li Y, Bai X, Li Y, Shi J, Hu D. Recent advances in hypertrophic scar. Histol Histopathol. 2018; 33: 27-39.

[12] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science (New York, NY). 2020; 367: eaau6977. https://doi.org/10.1126/science.aau6977.

[13] Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015; 13: 17-24.

[14] Wu P, Zhang B, Shi H, Qian H, Xu W. MSC-exosome: a novel cell-free therapy for cutaneous regeneration. Cytotherapy. 2018; 20: 291-301.

[15] An Y, Lin S, Tan X, Zhu S, Nie F, Zhen Y, et al. Exosomes from adipose-derived stem cells and application to skin wound healing. Cell Prolif. 2021; 54: e12993.

[16] Li Y, Zhang J, Shi J, Liu K, Wang X, Jia Y, et al. Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis. Stem Cell Res Ther. 2021; 12: 221.

[17] Li C, Wei S, Xu Q, Sun Y, Ning X, Wang Z. Application of ADSCs and their exosomes in scar prevention. Stem Cell Rev Rep. 2022; 18: 952-67.

[18] Wu ZY, Zhang HJ, Zhou ZH, Li ZP, Liao SM, Wu ZY, et al. The effect of inhibiting exosomes derived from adipose-derived stem cells via the TGF-β1/Smad pathway on the fibrosis of keloid fibroblasts. Gland Surg. 2021; 10: 1046-56.

[19] Zhang W, Bai X, Zhao B, Li Y, Zhang Y, Li Z, et al. Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp Cell Res. 2018; 370: 333-42.

[20] Zhang J, Li Y, Liu J, Han F, Shi J, Wu G, et al. Adiponectin ameliorates hypertrophic scar by inhibiting yes-associated protein transcription through SIRT1-mediated deacetylation of C/EBP β and histone H3. iScience. 2022; 25: 105236.

[21] Shen K, Jia Y, Wang X, Zhang J, Liu K, Wang J, et al. Exosomes from adipose-derived stem cells alleviate the inflammation and oxidative stress via regulating Nrf2/HO-1 axis in macrophages. Free Radic Biol Med. 2021; 165: 54-66.

[22] Shen K, Wang X, Wang Y, Jia Y, Zhang Y, Wang K, et al. miR-125b-5p in adipose derived stem cells exosome alleviates pulmonary microvascular endothelial cells ferroptosis via Keap1/Nrf2/GPX4 in sepsis lung injury. Redox Biol. 2023; 62: 102655.

[23] Liu SY, Wu JJ, Chen ZH, Zou ML, Teng YY, Zhang KW, et al. The m(6)a RNA modification modulates gene expression and fibrosis-related pathways in hypertrophic scar. Front Cell Dev Biol. 2021; 9: 748703.

[24] Son D, Harijan A. Overview of surgical scar prevention and management. J Korean Med Sci. 2014; 29: 751-7.

[25] Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022; 298: 101530.

[26] Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br J Dermatol. 2015; 173: 370-8.

[27] Monavarian M, Kader S, Moeinzadeh S, Jabbari E. Regenerative scar-free skin wound healing. Tissue Eng Part B Rev. 2019; 25: 294-311.

[28] Bainbridge P.Wound healing and the role of fibroblasts. J Wound Care. 2013; 22: 10-2.

[29] Driskell RR, Watt FM. Understanding fibroblast heterogeneity in the skin. Trends Cell Biol. 2015; 25: 92-9.

[30] Thulabandu V, Chen D, Atit RP. Dermal fibroblast in cutaneous development and healing. Wiley Interdiscip Rev Dev Biol. 2018; 7: 10. https://doi.org/10.1002/wdev.307.

[31] Karsdal MA, Nielsen SH, Leeming DJ, Langholm LL, Nielsen MJ, Manon-Jensen T, et al. The good and the bad collagens of fibrosis-their role in signaling and organ function. Adv Drug Deliv Rev. 2017; 121: 43-56.

[32] Jiang D, Christ S, Correa-Gallegos D, Ramesh P, Kalgudde Gopal S, Wannemacher J, et al. Injury triggers fascia fibroblast collective cell migration to drive scar formation through N-cadherin. Nat Commun. 2020; 11: 5653.

[33] Gibb AA, Lazaropoulos MP, Elrod JW. Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ Res. 2020; 127: 427-47.

[34] Pakshir P, Noskovicova N, Lodyga M, Son DO, Schuster R, Goodwin A, et al. The myofibroblast at a glance. J Cell Sci. 2020; 133: jcs227900. https://doi.org/10.1242/jcs.227900.

[35] Brewer CM, Nelson BR, Wakenight P, Collins SJ, Okamura DM, Dong XR, et al. Adaptations in hippo-yap signaling and myofibroblast fate underlie scar-free ear appendage wound healing in spiny mice. Dev Cell. 2021; 56: 2722-40.e6.

[36] Mia MM, Singh MK. New insights into hippo/YAP Signaling in fibrotic diseases. Cell. 2022; 11: 2065. https://doi.org/10.3390/cells11132065.

[37] Zhang T, He X, Caldwell L, Goru SK, Ulloa Severino L, Tolosa MF, et al. NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling. Sci Transl Med. 2022; 14: eaaz4028.

[38] Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, et al. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018; 292: 76-83.

[39] Liu J, Jin J, Liang T, Feng XH. To Ub or not to Ub: a regulatory question in TGF-β signaling. Trends Biochem Sci. 2022; 47: 1059-72.

[40] Zi Z, Chapnick DA, Liu X. Dynamics of TGF-β/Smad signaling. FEBS Lett. 2012; 586: 1921-8.

[41] Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends in genetics: TIG. 2022; 38: 613-26.

[42] Ferragut Cardoso AP, Banerjee M, Nail AN, Lykoudi A, States JC. miRNA dysregulation is an emerging modulator of genomic instability. Semin Cancer Biol. 2021; 76: 120-31.

[43] Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol. 2012; 19: 586-93.

[44] Wan X, Chen S, Fang Y, Zuo W, Cui J, Xie S. Mesenchymal stem cell-derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA-29b-3p in idiopathic pulmonary fibrosis. J Cell Physiol. 2020; 235: 8613-25.

[45] Ma C, Qi X, Wei YF, Li Z, Zhang HL, Li H, et al. Amelioration of ligamentum flavum hypertrophy using umbilical cord mesenchymal stromal cell-derived extracellular vesicles. Bioactive materials. 2023; 19: 139-54.

[46] Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi H, et al. Umbilical cord-derived mesenchymal stem cell-derived Exosomal MicroRNAs suppress Myofibroblast differentiation by inhibiting the transforming growth factor-β/SMAD2 pathway during wound healing. Stem Cells Transl Med. 2016; 5: 1425-39.

[47] Nagpal V, Rai R, Place AT, Murphy SB, Verma SK, Ghosh AK, et al. MiR-125b is critical for fibroblast-to-Myofibroblast transition and cardiac fibrosis. Circulation. 2016; 133: 291-301.